"In 2018 my lab was working on STING. Noxopharm contacted me to see if I would be interested in conducting research on idronoxil, the active ingredient of Veyonda®. The rationale at the time was that idronoxil would activate the STING pathway, which is involved in anti-tumour immunity. We discovered that idronoxil was a strong inhibitor of STING signalling in late October 2019. This was a key breakthrough. I knew this was the exact opposite of what we had set out to demonstrate for Noxopharm, but I saw the potential of this discovery since it made idronoxil the first human-ready inhibitor of STING signalling."
Think that one through for a minute.
- Forums
- ASX - By Stock
- NOX
- Latest Newsletter
Latest Newsletter, page-3
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
6.7¢ |
Change
0.001(1.52%) |
Mkt cap ! $19.57M |
Open | High | Low | Value | Volume |
6.7¢ | 6.7¢ | 6.7¢ | $818 | 12.21K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 17790 | 6.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 4049 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 17790 | 0.067 |
1 | 24715 | 0.066 |
1 | 15000 | 0.065 |
1 | 10000 | 0.064 |
1 | 100000 | 0.062 |
Price($) | Vol. | No. |
---|---|---|
0.070 | 4049 | 1 |
0.079 | 11999 | 1 |
0.080 | 12099 | 2 |
0.081 | 22345 | 2 |
0.090 | 52000 | 3 |
Last trade - 15.44pm 12/07/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |